Allogene Therapeutics, Inc. (ALLO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.09-8.40%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · ALLO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 387.3% |
| Our one-year growth estimate | diamond | 76.6% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 310.7 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-04 · Compared with 66 industry peers
ALLO — CFO transition
Dated 2026-09-02
CFO — Geoffrey Parker: The CFO is retiring with advance notice, which constitutes an orderly succession rather than a sudden loss of a senior executive.
Why it matters: The trial tests whether cema-cel delays or prevents relapse after first-line treatment. EFS results can show whether early MRD clearance leads to patient benefit.
Watch forThe mid-2027 interim EFS analysis shows fewer EFS events with cema-cel than with observation. This matches the trial's goal of a 50% risk reduction.
Also watch forThe interim analysis shows no clear EFS benefit, or it is delayed past mid-2027.
Why it matters: The company reported $423.6 million in cash and a runway into 2029. New cash figures or a changed runway can show whether trial spending remains funded.
Watch forThe November 5 update keeps the cash runway into 2029 and reports cash near or above the June 30 level of $423.6 million.
Also watch forThe update moves the stated runway earlier than 2029 or reports a sharp cash drop without a new funding source.
Why it matters: More active sites can support enrollment in the 220-patient trial. A shortfall could put the planned 2027 enrollment finish at risk.
Watch forAllogene reports about 100 active ALPHA3 sites by December 31, 2026. Enrollment remains on pace to finish by year-end 2027.
Also watch forAllogene reports far fewer than 100 active sites, or a delay to the year-end 2027 enrollment goal.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$237 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $721 loss on $10,000 · 7.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,438 loss on $10,000 · 64.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.